Haemonetics Shares Surge 7% Following Supply Agreement with CSL Limited

Key Facts

1Haemonetics shares rose approximately 7% in premarket trading following the announcement of a new supply agreement.

2Haemonetics entered the agreement with CSL Limited, an Australian biopharmaceutical firm.

In a move reflecting investor optimism toward strategic partnerships in the MedTech sector, Haemonetics shares rose approximately 7% in premarket trading. This surge followed the company's announcement of a new supply agreement with CSL Limited, a major biopharmaceutical firm based in Australia. According to reports, the agreement was disclosed in a regulatory filing, bolstering expectations regarding the company's future revenue stability.

This agreement links Haemonetics with one of the largest global players in the biopharma sector, strengthening the company's position in the blood management solutions market. Based on available data, the partnership with CSL Limited provides strong growth potential given the Australian firm's industry weight. Per market data, CSLLY shares closed at $24.11 (close of August 14, 2026), reaching a daily high of $24.27.

Traders are currently monitoring the sustainability of this price momentum for Haemonetics as the market absorbs the details of the supply deal. Looking at price levels recorded on August 14, 2026, CSLLY is trading within a stable range, while updated price data for CMXHF is currently unavailable. Future focus will remain on any additional disclosures regarding the agreement's duration or projected financial value.

Sources:

Seeking Alpha